DDInter1607 DDInter1701
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Sonidegib
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ranitidine
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sonidegib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Ranitidine
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sonidegib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Dexlansoprazole
Dexlansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sonidegib
Ritonavir {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sonidegib
Ritonavir {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Ranitidine
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sonidegib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sonidegib
Ritonavir {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sonidegib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sonidegib
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Sonidegib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Sonidegib
Ritonavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ranitidine (Compound) and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Dexlansoprazole and Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Ritonavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Ritonavir (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Ranitidine (Compound) and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Ritonavir (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Ritonavir (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Sonidegib